References
- Grillo-Lopez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002;2: 485–493.
- Witzig TE, Fishkin P, Gordon LI, et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011;52:1188–1199.
- Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
- Vose JM, Bierman PJ, Loberiza FR Jr, et al. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007;48:683–690.
- Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27:766–777.
- Fukuno K, Tsurumi H, Yamada T, et al. Radioimmunotherapy with 90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma. Leuk Lymphoma 2013;54:2731–2733.
- Munoz AS, Rioveros AA, Cabanayan-Casasola CB, et al. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc 2008;40:2218–2221.
- Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002;74: 1207–1210.
- Jillella AP, Dainer PM, Kallab AM, et al. Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J Hematol 2002;71:219–222.
- Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010;5:2188–2198.
- Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923–924.
- Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215–1226.
- Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–232.
- Garnier-Viougeat N, Rixe O, Paintaud G, et al. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant 2007; 22:975.
- Kelly RJ, Hill A, Arnold LM, et al. Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure. Leuk Res 2011;35:560–562.
- Baechler S, Hobbs RF, Prideaux AR, et al. Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan. Cancer Biother Radiopharm 2008;23:633–639.
- Chiesa C, Botta F, Coliva A, et al. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Eur j Nucl Med Mol Imaging 2009;36:1745–1757.
- Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44: 465–474.